Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai Pharma to Raise $1.2 Billion in Hong Kong IPO

publication date: Sep 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Pharmaceuticals Holding Co. will stage an IPO in Hong Kong to raise 8 billion RMB ($1.2 billion) that it will use for acquisitions. A state-owned enterprise, Shanghai Pharma is a rival of Sinopharm (HKEX: 1099) in the China pharmaceutical distribution business, and its IPO seeks almost the same amount as Sinopharma’s IPO in Hong Kong one year ago. More details....

Stock Symbol: (SHEX: 601607)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...